Misplaced Pages

Golidocitinib

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.

This is an old revision of this page, as edited by Innerstream (talk | contribs) at 19:56, 23 December 2024 (new page). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Revision as of 19:56, 23 December 2024 by Innerstream (talk | contribs) (new page)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Pharmaceutical compound
Golidocitinib
Clinical data
Trade names高瑞哲
Other namesAZD-4205, AZD4205, JAK1-IN-3
Legal status
Legal status
  • Rx in China
Identifiers
IUPAC name
  • (2R)-N-pyrimidin-4-yl]-1H-indol-7-yl]-2-(4-methylpiperazin-1-yl)propanamide
CAS Number
PubChem CID
UNII
Chemical and physical data
FormulaC25H31N9O2
Molar mass489.584 g·mol

Golidocitinib is a pharmaceutical drug for the treatment of cancer. In June 2024, it was given conditional approval in China for the treatment of relapsed or refractory peripheral T-cell lymphoma.

Golidocitinib is classified as a Janus kinase inhibitor.


References

  1. . doi:10.1007/s40265-024-02089-2. {{cite journal}}: Cite journal requires |journal= (help); Missing or empty |title= (help)
  2. . doi:10.1016/S1470-2045(23)00589-2. {{cite journal}}: Cite journal requires |journal= (help); Missing or empty |title= (help)
  3. . doi:10.1182/blood-2024-211891. {{cite journal}}: Cite journal requires |journal= (help); Missing or empty |title= (help)
Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Misplaced Pages by expanding it.

Categories: